Vaxart, Inc. was granted a conditional continuation of its Nasdaq listing on August 27, 2025, after appealing a delisting decision due to its stock price falling below $1.00. The company must complete a reverse stock split by October 6, 2025, and show compliance with Nasdaq’s requirements by October 17, 2025.